Urolithiasis

, Volume 41, Issue 3, pp 247–252 | Cite as

Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy

  • Yuan-Ju Lee
  • Kuo-How Huang
  • Hung-Ju Yang
  • Hong-Chiang Chang
  • Jun Chen
  • Teng-Kai Yang
Original Paper

Abstract

The objective of this study is to evaluate the effects of solifenacin on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral stent insertion following URSL were consecutively recruited and received solifenacin postoperatively. Another 70 age- and sex-matched subjects without solifenacin therapy were enrolled as a control group. The clinical data including stone and stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the lower urinary tract symptoms, stent-related body pain and hematuria 2 weeks after operation. The severity of stent-related symptoms was compared between two groups. The mean age was 53.8 in solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics, stent size, position and curl completeness were similar in both groups. Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. As for stent-related body pain, solifenacin group had significantly less flank, abdominal, urethral pain and hematuria scores (all p < 0.05). The solifenacin versus control group showed significant benefits in lower urinary tract symptoms, stent-related pain and hematuria in both genders (all p < 0.05). Four subjects encountered minor adverse events (5.7 %) and one had urinary retention (1.4 %) in solifenacin group. For patients undergoing URSL and double-J stent indwelling, postoperative solifenacin use was effective and well-tolerated for the treatment of lower urinary tract symptoms, stent-related body pain and hematuria irrespective of genders.

Keywords

Solifenacin Ureteral stent Lower urinary tract symptoms 

Notes

Conflict of interest

All authors declare that they have no conflict of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending).

References

  1. 1.
    Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069 (discussion 1069)PubMedCrossRefGoogle Scholar
  2. 2.
    Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Grande M, Giacometti M, Ferrari N, Rivalta M, Bianchi G (2007) Indwelling ureteral stents and sexual health: a prospective, multivariate analysis. J Urol 178:229–231PubMedCrossRefGoogle Scholar
  3. 3.
    Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S, Sacco R, D’Armiento M (2005) Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 48:673–678PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas R (1993) Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol 7:137–140PubMedCrossRefGoogle Scholar
  5. 5.
    Park SC, Jung SW, Lee JW, Rim JS (2009) The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 23:1913–1917PubMedCrossRefGoogle Scholar
  6. 6.
    Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M (2008) Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 22:651–656PubMedCrossRefGoogle Scholar
  7. 7.
    Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176PubMedCrossRefGoogle Scholar
  8. 8.
    Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P (2011) Is there a role for alpha-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 186:928–934PubMedCrossRefGoogle Scholar
  9. 9.
    Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 63:1702–1714PubMedCrossRefGoogle Scholar
  10. 10.
    Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109:702–708PubMedCrossRefGoogle Scholar
  11. 11.
    Lim KT, Kim YT, Lee TY, Park SY (2011) Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 52:485–488PubMedCrossRefGoogle Scholar
  12. 12.
    Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064PubMedCrossRefGoogle Scholar
  13. 13.
    Gunlusoy B, Degirmenci T, Arslan M, Kozacyoglu Z, Minareci S, Ayder AR (2008) Is ureteral catheterization necessary after ureteroscopic lithotripsy for uncomplicated upper ureteral stones? J Endourol 22:1645–1648PubMedCrossRefGoogle Scholar
  14. 14.
    Chen YT, Chen J, Wong WY, Yang SS, Hsieh CH, Wang CC (2002) Is ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy? A prospective, randomized controlled trial. J Urol 167:1977–1980PubMedCrossRefGoogle Scholar
  15. 15.
    Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM (2006) Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 67:35–39PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, Landman J (2010) Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol 183:598–602PubMedCrossRefGoogle Scholar
  17. 17.
    Joshi HB, Chitale SV, Nagarajan M, Irving SO, Browning AJ, Biyani CS, Burgess NA (2005) A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J Urol 174:2303–2306PubMedCrossRefGoogle Scholar
  18. 18.
    Candela JV, Bellman GC (1997) Ureteral stents: impact of diameter and composition on patient symptoms. J Endourol 11:45–47PubMedCrossRefGoogle Scholar
  19. 19.
    Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedCrossRefGoogle Scholar
  20. 20.
    Herschorn S, Stothers L, Carlson K et al (2010) Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 183:1892–1898PubMedCrossRefGoogle Scholar
  21. 21.
    van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183PubMedCrossRefGoogle Scholar
  22. 22.
    Osman Y, El-Tabey N, Refai H, Elnahas A, Shoma A, Eraky I, Kenawy M, El-Kapany H (2008) Detection of residual stones after percutaneous nephrolithotomy: role of nonenhanced spiral computerized tomography. J Urol 179:198–200 discussion 200PubMedCrossRefGoogle Scholar
  23. 23.
    Park J, Hong B, Park T, Park HK (2007) Effectiveness of noncontrast computed tomography in evaluation of residual stones after percutaneous nephrolithotomy. J Endourol 21:684–687PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Yuan-Ju Lee
    • 1
  • Kuo-How Huang
    • 1
  • Hung-Ju Yang
    • 1
    • 2
  • Hong-Chiang Chang
    • 1
  • Jun Chen
    • 1
  • Teng-Kai Yang
    • 1
    • 2
  1. 1.Department of UrologyNational Taiwan University Hospital, and National Taiwan University College of MedicineTaipeiTaiwan
  2. 2.Division of Urology, Department of Surgery, Cardinal Tien Hospital, Yonghe Branch, and School of MedicineFu Jen Catholic UniversityYonghe Dist., New Taipei CityTaiwan

Personalised recommendations